In leukemic cells exposed to 2-chlorodeoxyadenosine (2-CdA), levels of the nucleoside drug and its phosphate metabolites decay with time in the absence of external 2-CdA; an intrinsic part of this process is the efflux of 2-CdA. The effects of nitrobenzylthioinosine (NBMPR) and of dipyridamole (DPM), both potent inhibitors of es (e, equilibrative; s, sensitive to NBMPR) nucleoside transport processes, were studied in four lines of cultured leukemic lymphoblasts. Suspensions of 2-CdA-loaded cells were diluted 10-fold with 2-CdA-free medium to initiate the cellular 2-CdA decay processes, which followed a biexponential time course. When diluting media contained NBMPR or DPM, intracellular levels of 2-CdA and its metabolites were substantially increased (P Ͻ 0.001) compared with cells in media lacking the transport inhibitors, and 2-CdA loss followed a monoexponential time course. As a consequence, the AUCs (area under time-course plots of intracellular 2-CdA and its metabolites) were significantly (P Ͻ 0.001) lower in untreated control cells compared to inhibitor-treated cells. These results suggest that nucleoside transport processes contribute to the efflux of 2-CdA from the cultured lymphoblasts. The cytotoxicity of 1-h exposure to 2-CdA of Reh-A2 and CCRF-CEM cells was enhanced three-fold by subsequent exposure to 0.5 M NBMPR relative to that of control cells subjected to the same manipulations without NBMPR exposure. However, before such a strategy may be considered to have a therapeutic application, careful examination of effects in normal lymphocytes and ex vivo leukemic lymphoblasts must first be undertaken. Leukemia (2000) 14, 52-60.
Introduction
2-Chlorodeoxyadenosine (2-CdA) is a purine nucleoside analog that has shown notable activity in the treatment of the indolent lymphoid malignancies. 1, 2 Clinical trials of 2-CdA treatment of pediatric patients with acute leukemias have shown promising results. 3, 4 Following transporter-mediated entry into cells, 5 2-CdA is anabolised to the cytotoxic metabolite, 2-CdA 5Ј-triphosphate (2-CdATP). 6 In proliferating cells, cytotoxic effects of 2-CdATP are believed to include incorporation into DNA, 7 inhibition of ribonucleotide reductase activity, 8 and inhibition of DNA polymerases ␣ and ␤. 9 In resting cells, the accumulation of 2-CdATP is believed to reduce the cell's ability to repair DNA strand breaks through inhibition of DNA polymerase ␤; the unrepaired breaks in DNA may activate poly(ADP)ribosylation with the result that cellular depletion of NAD and ATP may initiate apoptosis. 8 Logically, the cytotoxicity of 2-CdA must depend upon entry into target cells via several nucleoside transporters; [10] [11] [12] [13] [14] however, membrane transport has not been shown experimentally to be a determinant of 2-CdA cytotoxicity. a substrate for several nucleoside transport (NT) processes, 15 including the equilibrative NT processes, es and ei, 10 and the Na + -linked concentrative transporters, cif, 11 cit, 12 cib 13 and cs. 14 In the terminology of Belt and colleagues, 'es' NT processes are equilibrative and sensitive to the classical NT inhibitor nitrobenzylthioinosine (NBMPR), 'ei' NT processes are equilibrative and insensitive to NBMPR, 'cif ' processes refer to concentrative Na + -linked NT processes that are both insensitive to NBMPR and utilize formycin B, 'cit' processes refer to concentrative Na + -linked NT processes that are both insensitive to NBMPR and utilize thymidine, and 'cib' processes refer to concentrative Na + -linked NT processes that are both insensitive to NBMPR and utilize a broad range of permeants. 10 Cs NT processes refer to concentrative Na + -dependent processes that are sensitive to NBMPR. Although several NT processes have been identified in both fresh leukemia cells and in human leukemia cell lines, [14] [15] [16] [17] [18] the es transporter appears to be the most commonly expressed NT process in human leukemia cells. 16, 17 In the four lymphoblastic cell lines examined in this study, the es NT process was the only NT process observed.
Intracellular levels of 2-CdA and its metabolites have been shown to decline rapidly when cells are placed in 2-CdA-free medium.
3, 16 Santana et al 3 reported half-lives of 1.29 and 2.47 h for 2-CdAMP and 2-CdATP, respectively, in 2-CdAloaded leukemic blasts from pediatric acute leukemia patients. It has also been reported that levels of 2-CdA and metabolites thereof, decayed in a biexponential manner in leukemic cells from chronic lymphocytic leukemia (CLL) patients. 16 In that study, when the 2-CdA-loaded cells were suspended in 2-CdA-free medium that contained 0.5 M NBMPR, a significant reduction in 2-CdA efflux was observed in 13 out of the 19 samples examined. Because the decay in 2-CdA levels was blocked in the presence of NBMPR, it was reasoned that the es transporter-mediated efflux process was intrinsic to the decay process. The inability of NBMPR to inhibit efflux in some patients in that study may have been due in part to NT processes that were insensitive to the transport inhibitor.
Cytosine arabinoside (araC), another nucleoside analog, is widely used in the treatment of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). 19 Other studies have demonstrated (1) that in vitro retention of araCTP in AML cells correlated with duration of remission of patients receiving araC therapy, 20 and (2) that levels of araCTP incorporation into DNA correlated with the cytotoxic potential of this agent. 21 Furthermore, in fresh human leukemic myeloblasts, intracellular araCTP levels were increased by dipyridamole (DPM) blockade of araC efflux. 22 In the present study, the effect of NT inhibitors on the decay of intracellular 2-CdA and its metabolites in cultured lymphoblasts was examined. It is hypothesized that a 'retention tactic', that is, inhibition of 2-CdA efflux with NT inhibitors such as NBMPR or DPM would, through blockade of 2-CdA efflux, sustain cellular levels of 2-CdA and its active metabolites and, thereby, enhance the cytotoxicity of 2-CdA exposure. In these studies, the cytotoxicity of the 2-CdA-inhibitor sequence was evaluated using an in vitro tetrazolium dye reduction assay (MTT) of cell proliferation. The MTT assay was used in this study since it has been shown that in vitro sensitivity data obtained with this assay may be a good predictor of clinical outcome in pediatric ALL and acute nonlymphoblastic leukemia. 23, 24 Furthermore, a number of retrospective studies of chemotherapy in adult AML found the MTT assay to be a good predictor of clinical outcome. 33 or in Dulbecco's N-methylglucammonium medium (DNMG) at a concentration of 1 × 10 7 cells/ml for transport studies. DNMG is similar to DPBS with the exception that Na + ions are replaced by NMG + ions. In preparation for the MTT assay, cells from stock solutions were resuspended in RPMI 1640 medium containing 2 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer and 10% FBS (comprising RH10F medium) at a concentration of 3-5 × 10 5 cells/ml.
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Materials and methods
Chemicals
Nucleoside transport studies Nucleoside fluxes:
The NT processes expressed in cells of the four cultured lines used in this study were identified (that is, the 'NT phenotype' was defined) by procedures described previously.
14 Nucleoside fluxes were measured in a 37°C warm room. Briefly, initial rates of nucleoside uptake were determined from time courses of cellular uptake of 3 H-2-CdA.
Leukemia
Inward zero-trans fluxes were initiated by rapidly mixing 100-l portions of 2 M or 200 M 3 H-2-CdA with 100-l portions of cell suspension (10 6 cells) that had previously been layered over 100 l of transport oil in a 1.5-ml microcentrifuge tube. Cells were suspended either in DPBS, or in variations of this medium as specified in Results. Cellular uptake of 3 H-permeant was measured over intervals of 3-15 s, which were ended by pelleting cells (20 s, 15 000 g) under 'transport oil' in an Eppendorf Model 5412 microcentrifuge.
3 H-2-CdA uptake during the pelleting operation was considered equivalent to that during a 2-s incubation interval. 34 To estimate timezero values for cellular uptake of 3 H-2-CdA, cells suspended in DPBS containing 10 M DPM were cooled in an ice-bath for 10 min prior to rapid addition of 3 H-2-CdA (as in influx assays), which was followed by immediate centrifugation. To measure 3 H-activity in cell pellets, the supernatant fractions and oil layers were removed by aspiration, and tip portions of the assay tubes (which included cell pellets) were placed in scintillation vials. Cells were lysed overnight with 500 l of 5% Triton X-100. Four-ml portions of Ecolite scintillation fluid (ICN, Costa Mesa, CA, USA) were added to the lysates, and 3 H-activities of the cell samples were then determined by liquid scintillation counting. Intracellular water volumes in cell pellets were estimated by subtracting the extracellular water space (estimated by measuring cell pellet content of 3 H-polyethylene glycol or of 14 C-sucrose after a 3-s interval of exposure) from the total pellet water (determined by measuring 
Retention experiments:
Cultured ALL cells in DPBS (10 7 cells/ml) were incubated with 1 M 3 H-2-CdA for 1 h at 37°C to 'load' cells with 3 H-2-CdA. Following loading, efflux of 3 H-2-CdA was initiated by diluting cell suspensions 10-fold, with either DPBS (control), or with DPBS containing NT inhibitors. One-ml portions (10 6 cells) were sampled from those suspensions at graded intervals. Cells were pelleted under oil (20 s, 15 000 g) to end intervals of efflux. All assays were performed in triplicate and experiments were repeated three times. 3 H-activity of cell pellets was determined as for assays of nucleoside influx. Efflux data are reported as equivalents of 2-CdA (pmol/10 6 cells), which include 2-CdA, the mono-, di-and triphosphate metabolites, and possibly 2-chloroadenine.
Time courses of the decrease in cellular 3 H-2-CdA content were analyzed by fitting either one-phase or two-phase exponential decay curves to the efflux data (GraphPad Prism, Version 1.0) as follows:
one-phase, exponential decay Y = y 0 + Ae where Y is the concentration of 2-CdA and its metabolites in the cell, y 0 is the plateau of the elimination curve, ␣ and ␤ are the elimination rate constants, A and B are the respective intercepts, and e is the base of natural logarithms. The halflives of decay (t . ) were calculated as 0.693/␣ and 0.693/␤. Areas under the 2-CdA equivalents vs time curves between 0 and 2 h (AUC 0-2h ) were calculated using the trapezoidal rule (GraphPad Prism, Version 1.0).
Leukemia
Cytotoxicity of 2-CdA and NBMPR combinations in cultured lymphoblasts
The in vitro sensitivity of the cultured lymphoblasts to 2-CdA and to the 2-CdA/NBMPR combination was determined using an MTT dye reduction assay. 35 Reh-A2 and CEM cell suspensions in RH10F medium (5 × 10 5 and 3 × 10 5 cells/ml, respectively) were exposed at 37°C to graded concentrations of 2-CdA for 1 h to 'load' cells with that agent. Plates were incubated at 37°C in a humidified atmosphere of 5% CO 2 in air for 69 h. After incubation, 30 l of MTT solution (1 mg/ml) in RH10F medium was added to each well and the plates were incubated for a further 2 h. During the 2-h interval of MTT reduction, the microcultures were protected from light. The plates were then centrifuged (7 min, 50 g) and the supernatant fluid was aspirated from each well. Following this, the crystalline formazan product was dissolved by the addition to each well of 150 l of dimethylsulfoxide (spectrophotometric grade, Aldrich, Milwaukee, WI, USA) and the absorbance of the well solutions was measured in a microplate reader (Titertek Multiskan Plus, ICN Biomedicals, Mississauga, ON, Canada) at 540 nm (A 540 ). The A 540 of the microwell solutions was shown by experiment to be proportional to cell viability. Cell viabilities in the test wells were expressed as percentages of those in control wells. The cytotoxic effects of 2-CdA (with and without NBMPR) toward cultured lymphoblasts were evaluated with the MTT assay by determining the 2-CdA concentrations that would result in a half-maximal response (IC 50 ) in the MTT assay.
Metabolism of 3 H-2-CdA in Reh-A2 and CEM cells
Reh-A2 and CEM cells (100 l) were suspended in RH10F medium at 10 7 cells/ml and exposed to 1 M 3 H-2-CdA at 37°C for 1 h. After exposure to 2-CdA (loading), portions of the cell suspension were diluted 10-fold with RH10F medium without additives (control), or with RH10F medium containing 0.5 M NBMPR, and incubated at 37°C for a further 2 h. Following incubation, the cell suspensions were chilled in an icebath for 10 min and centrifuged (30 s, 15 000 g) at 4°C, after which the cell pellets were washed with 0.5 ml ice-cold PBS and recovered by centrifugation at 4°C. The wash medium was discarded and the cells were extracted with 70% methanol. Cellular 2-CdA and its metabolites were determined by HPLC analysis of the methanol extracts. The extracts were dried in an ice bath under a stream of nitrogen and resuspended in 100 l of the initial mobile phase buffer (5 mM NH 4 H 2 PO 4 ). Samples were applied to a Whatman Partisil 10 SAX anion exchange column, 4.6 × 250 mm, and eluted at 2 ml/min (22°C) with a gradient system that changed linearly from 5 mM ammonium phosphate (pH 4.0) to 700 mM ammonium phosphate (pH 4.8) over a 30-min interval. Fractions (0.66 ml) were collected every 20 s for 32 min. Ecolite (4 ml) scintillation solution was added to each fraction and the 3 H-activity of each was determined by liquid scintillation counting.
Statistical analysis
Unless otherwise stated, Student's t-test was used to measure statistical significance and paired t-tests were used to compare IC 50 values obtained from the cytotoxicity assays. The Tukey multiple comparisons test was used to compare intracellular 2-CdA concentrations in retention experiments. Statistical analyses were performed at a two-sided significance level of 0.05. Data are reported as means ± s.e.m., unless otherwise stated.
Results and discussion
Nucleoside transport processes expressed in lymphoblasts from four ALL cell lines
The NT processes expressed in cultured lymphoblasts was determined by measuring inward fluxes of 2-CdA in these cells. A low nucleoside concentration (1 M) was used to increase the possibility of identifying a Na + -dependent process, since equilibrative transporters tend to have a lower affinity for their substrates than the concentrative transporters, 36, 37 and to determine the NT processes contributing specifically to 1 M 2-CdA transport, the concentration of 2-CdA used in the remainder of the study. Time courses (3-15 s) of 3 H-2-CdA uptake by the rapid sampling method yielded initial rates of uptake for 2-CdA under various conditions; in other words, rates of 2-CdA transport were calculated.
NT processes were identified by the effects of NT inhibitors and by the effects of replacement of Na + ions on the initial rates of 2-CdA uptake. The es NT process was recognized as a Na + -independent component of 2-CdA uptake that was inhibited by NBMPR. Ei transport activity was measured as the difference between Na + -independent fluxes of 2-CdA in the presence of NBMPR and DPM. The difference between 2-CdA uptake in Na + -replete (DPBS) and Na + -deficient (DNMG) medium was used to identify the expression of Na + -dependent NT processes. Concentrations of NBMPR and DPM were selected from previous experiments which identified concentrations of inhibitor that completely inhibited the uptake of 2-CdA by the es process. Figure 1 shows the time courses of 1 M and 100 M 3 H-2-CdA uptake in Reh-A2 and KM3-2B cells; these data show that the flux assay technology yields data that define the initial rates of 2-CdA uptake by the cultured lymphoblasts, that is that bona fide nucleoside fluxes are measured by this technology. The initial rate of cellular uptake of permeant is by convention the unidirectional inward flux of that permeant. In the presence of micromolar concentrations of NBMPR and DPM, the uptake of both 1 M and 100 M 2-CdA was inhibited in both cell lines, indicating the absence of ei transporter activity. There was also little difference between 2-CdA fluxes in Na + -replete and Na + -deficient media, suggesting that the es transporter was the principal contributor to 2-CdA uptake in the lymphoblasts. Table 1 summarizes the NT processes contributing to 1 M 2-CdA uptake in cells of the four ALL lymphoblast lines. The es transporter was essentially the only NT process detectable.
Modulation of the intracellular pharmacokinetics of 2-CdA by inhibitors of nucleoside transport
The effects of NBMPR and DPM on the retention and the cytotoxicity in lymphoblasts of 2-CdA were investigated in the present study. Low concentrations (0.5-1 M) of both NBMPR and DPM were used in the present study to block the efflux of 2-CdA, as higher concentrations of these agents may not be clinically relevant. 38, 39 In the experiment shown in Leukemia Figure 2 , cells were loaded with 2-CdA and metabolites thereof by incubation (37°C, 1 h) in medium containing 1 M 3 H-2-CdA. Earlier studies in fresh CLL cells in this laboratory suggested that the intracellular metabolites of 2-CdA were the mono-, di and triphosphate esters, and showed 2-CdA to be the principal efflux product. 16 In the present study, in cells of each of the four cultured lymphoblast lines, a biexponential decline in cell content of 2-CdA metabolites took place when suspensions of the drug-containing cells were diluted 10-fold with drug-free medium, that is, when extracellular concentrations of 2-CdA were abruptly reduced by 90% by dilution. Initial half-lives (t 1/2␣ ) of the total 2-CdA content of the lymphoblasts ranged from 0.04 to 0.09 h in the four cell lines tested (Table 2) ; terminal half-lives of cellular 2-CdA in the decay process ranged from 0.60 to 6.28 h. In contrast, the time courses of 2-CdA loss from cells in suspensions diluted with medium containing NT inhibitors, NBMPR and DPM, proceeded with a monoexponential decline of intracellular 2-CdA equivalents. The half-lives of 2-CdA in the loss processes in the cell lines ranged from 0.63 to 1.49 h when diluting medium contained 0.5 M NBMPR, 0.73 to 1.79 h in the presence of 1 M NBMPR, and 0.85 to 2.21 h in the presence of 1 M DPM (Table 2) .
In the present study, NBMPR and DPM significantly reduced rates of loss of 3 H-2-CdA (equivalents) from lymphoblasts of the four ALL cell lines, by converting the biexponential decline in intracellular 2-CdA levels to a monoexponential process. Because es is virtually the only transport process expressed in these cells and because efflux of 2-CdA equivalents was reduced by NT inhibitors, it appears that the es transporter participates in the loss of 2-CdA. The presence of NBMPR or DPM does not appear to affect the terminal halflife of 2-CdA efflux.
As the inhibitor effect was most pronounced in the early 
Table 2
Half (Table 3 ). There was no difference between the cellular retention of 2-CdA by NBMPR and DPM. These results indicate that NT inhibitors significantly enhanced the cellular retention of 2-CdA equivalents in cultured human lymphoblasts by slowing the loss of 2-CdA, likely through inhibition of the es transport process.
Chosen for the study were four human ALL cell lines in (Figure 2 ). The AUC (0-2h) values for the inhibitor-treated groups were significantly higher than the corresponding values for the untreated control group (P Ͻ 0.001, Tukey multiple comparisons test).
which the es nucleoside transporter was essentially the sole NT process expressed. This circumstance allowed demonstration of the retentive effects of NBMPR and DPM without loss of 2-CdA from the cell via NBMPR-insensitive NT processes. The operation of multiple NT processes in leukemic cells would likely influence attempts to manipulate transport fluxes of nucleoside drugs by means of NT inhibitors. For example, the expression of the cib NT process, or of other Na + -dependent systems that are insensitive to NBMPR, would probably increase cellular retention of 2-CdA and of nucleoside analogs by mediating influx of nucleoside analogs even in the presence of NT inhibitors that would block the es transporter-mediated efflux process. Alternatively, expression of the ei NT process would likely reduce the retentive effect by permitting 2-CdA efflux even in the presence of NBMPR.
Enhancement of 2-CdA cytotoxicity in the presence of NBMPR in Reh-A2 and CEM cells
In the present study, the effect of a delayed, secondary exposure to NBMPR on the cytotoxicity of 2-CdA was examined in Reh-A2 and CEM cells by using the MTT dye reduction assay. The use of 0.5 M NBMPR in the cytotoxicity assays was based upon three observations: (1) there was no significant difference between NBMPR and DPM to slow 2-CdA efflux; (2) a 0.5 M plasma concentration of NBMPR may be clinically achievable (unpublished data); and (3) DPM is highly bound to plasma proteins, reducing available DPM concentrations in plasma significantly and therefore its potential utility in clinical protocols. [39] [40] [41] As for the 'retention' experiments, cells were loaded with 2-CdA and cell suspensions were then diluted 10-fold with 2-CdA-free medium to initiate the efflux process in the presence or the absence of 0.5 M NBMPR. After a 2-h incubation period at 37°C, cells were washed and resuspended in drug-free medium and incubated for a further 69 h. Figure 3a and b shows concentration-effect plots for Reh-A2 and CEM cells exposed to 2-CdA alone or to the 2-CdA-NBMPR sequence. A statistically significant enhancement of cytotoxicity (P Ͻ 0.01) occurred when the efflux of 2-CdA was slowed by 0.5 M NBMPR. An approximately three-fold reduction in the IC 50 values for 2-CdA was found in cells exposed to the 2-CdA/NBMPR sequence (IC 50 values for 2-CdA in Reh-A2 and CEM cells exposed to the drug-inhibitor sequence were 3.5 ± 1.5 M and 12.9 ± 0.6 M, respectively), whereas IC 50 values for Reh-A2 and CEM cells exposed to 2-CdA alone were 12.4 ± 3.1 M and 34.5 ± 5.4 M, respectively. Exposure to NBMPR alone under these circumstances had no effect on cell growth (data not shown). In these experiments, the concentrations of 2-CdA producing a 50% reduction in cell viability are not absolute (because of the 10-fold dilution of the suspension of 2-CdA-loaded cells and the subsequent washing step) and, accordingly, IC 50 value estimates were based on the 2-CdA concentrations to which the cells were exposed prior to the 10-fold dilution. Despite this, the IC 50 values obtained are relative values which demonstrate the enhancement of 2-CdA cytotoxicity attributable to the secondary exposure of the 2-CdA-loaded cells to NBMPR. This effect, which was seen with both Reh-A2 and CEM lymphoblasts, was determined in cells exposed sequentially for short intervals to 2-CdA (1 h) and NBMPR (2 h) under conditions that matched those of the 'retention' experiments ( Figure 2) . It is not known whether longer periods of exposure to these agents would also yield enhanced cytotoxic effects. Furthermore, the results seen in Reh-A2 and CEM cells must be confirmed in experiments with fresh leukemic cells, to support a therapeutic application of this strategy.
Leukemia
Effect of NBMPR on the intracellular levels of 2-CdA and its metabolites in Reh-A2 and CEM cells
It is hypothesized that enhancement in 2-CdA cytotoxicity to lymphoblasts that resulted from secondary exposure to NBMPR was due to cellular retention of 2-CdA metabolites. To test this idea, levels of 2-CdA and its metabolites were measured in Reh-A2 and CEM cells exposed to 3 H-2-CdA and in cells exposed to the 2-CdA/NBMPR sequence. HPLC analysis of methanolic extracts of the cells revealed the presence of three labelled products together with the parent drug (Figures 4 and 5) . The products appeared to be the mono-, di-, and triphosphate metabolites of 2-CdA because of similarities in retention times of dAMP, dADP and dATP. The labelled peak designated as 2-CdA eluted with the same retention time as authentic 2-CdA. Table 4 reports cellular levels of 3 H-labelled 2-CdA and its metabolites formed in the presence or absence of 0.5 M NBMPR in cultured Reh-A2 and CEM cells. In Reh-A2 cells, a significant increase in the intracellular mono-, di, and triphosphate metabolites (P Ͻ 0.05) was apparent in cells also exposed to 0.5 M NBMPR relative to levels of the same metabolites in cells exposed to 3 H-2-CdA alone. An increase in intracellular 2-CdA levels was also observed in Reh-A2 cells, supporting the hypothesis that NBMPR enhances 2-CdA retention by blocking efflux via the es NT protein. However, this increase was not statistically significant (P = 0.07) in this instance. The presence of NBMPR in the suspending medium did not alter the percentage of each metabolite formed (data not shown). Figure 4 shows the enhanced retention by NBMPR of 2-CdA and its metabolites in Reh-A2 cells. Similar results ( Figure 5 and Table 4 ) were found in CEM cells; however, in the latter cells, only 2-CdATP levels were significantly (P Ͻ 0.05) increased in the presence of 0.5 M NBMPR. Yang and colleagues 22 reported little increase in cellular levels of araCTP in the presence of DPM in patient cells that expressed low es site numbers. The authors suggested that in cells with low NT expression, deamination of either araC or araCMP plays the major role in the net catabolism of araCTP and not the efflux of araC. However, the ability of NBMPR to sustain cellular levels of 2-CdA and its metabolites in patient cells with low es site numbers may not be affected to the same extent, as 2-CdA is resistant to deamination. 1, 2 In summary, NBMPR and DPM significantly reduced the loss of 2-CdA equivalents from cells from four lines of cultured ALL lymphoblasts by slowing the rapid initial phase of a 2-CdA efflux process. Because es was virtually the only NT process expressed in these cells and because loss of 2-CdA equivalents was reduced by NT inhibitors, it appears that the es transporter may mediate the initial phase of the 2-CdA efflux process. Before NBMPR is considered as a retentive agent in the therapeutic use of cytotoxic nucleosides, the effects of NBMPR/nucleoside combinations towards normal lymphoid cells must be examined to determine whether a selective enhancement of cytotoxicity towards leukemic cells can be achieved.
